The TRISTARDS Trial - ThRombolysIS Therapy for ARDS A Phase IIb/III Operationally Seamless, Open-label, Randomised, Sequential, Parallel-group Adaptive Study to Evaluate the Efficacy and Safety of Daily Intravenous Alteplase Treatment Given up to 5 Days on Top of Standard of Care (SOC) Compared With SOC Alone, in Patients With Acute Respiratory Distress Syndrome (ARDS) Triggered by COVID-19
Latest Information Update: 23 May 2024
At a glance
- Drugs Alteplase (Primary)
- Indications COVID-19 respiratory infection; SARS-CoV-2 acute respiratory disease
- Focus Registrational; Therapeutic Use
- Acronyms TRISTARDS
- Sponsors Boehringer Ingelheim
- 11 Feb 2024 This study has been completed in Portugal, according to European Clinical Trials Database record.
- 31 Jan 2024 This study has been completed in France, according to European Clinical Trials Database record.
- 15 Oct 2023 The trial has been completed in Spain, according to European Clinical Trials Database record.